Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
END-COVID
NCT04405739Phase 2Completed
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of molnupiravir in coronavirus disease 2019 (COVID-19). Started Jun 2020; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04405739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405739.